BCL2L2 and glioma: To first confirm the relationship between miR-29b and BCL2L2, we measured miR-29b and BCL2L2 protein or mRNA levels by quantitative real-time PCR and immunoblotting in various cancer cells, including gliomas (U251, U87MG, and U373) breast (MCF7 and MDA-MB-231), and lung (A549 and H460) cancer cell lines, and found that miR-29b was relatively downregulated in all except MDA-MB 231 cells (Figure 5A, top left).